#BEGIN_DRUGCARD DB03801

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
43575

# Chemical_Formula:
C7H14N2O4

# Chemical_IUPAC_Name:
(2S)-2-amino-6-(carboxyamino)hexanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Lysine Nz-Carboxylic Acid

# HET_ID:
KCX

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H14N2O4/c8-5(6(10)11)3-1-2-4-9-7(12)13/h5,9H,1-4,8H2,(H,10,11)(H,12,13)/t5-/m0/s1

# InChI_Key:
InChIKey=PWIKLEYMFKCERQ-YFKPBYRVSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3801

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
190.1971

# Molecular_Weight_Mono:
190.095356946

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1UAG

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-3.3

# Predicted_LogS:
-1.1

# Predicted_Water_Solubility:
1.35e+01 g/l

# Primary_Accession_No:
DB03801

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
17754054

# PubChem_Substance_ID:
46507407

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01965

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](CCCCNC(O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:38 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Cytoplasmic

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
Not Available

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
Not Available

# Drug_Target_10_Gene_Sequence:
Not Available

# Drug_Target_10_General_Function:
Involved in hydrolase activity

# Drug_Target_10_General_References:
12079340	Abendroth J, Niefind K, Schomburg D: X-ray structure of a dihydropyrimidinase from Thermus sp. at 1.3 A resolution. J Mol Biol. 2002 Jun 28;320(1):143-56.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
5436

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
50676

# Drug_Target_10_Name:
Hydrolase

# Drug_Target_10_Number_of_Residues:
458

# Drug_Target_10_PDB_ID:
1GKQ

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_10_Protein_Sequence:
>Hydrolase
PLLIKNGEIITADSRYKADIYAEGETITRIGQNLEAPPGTEVIDATGKYVFPGFIDPHVH
IYLPFMATFAKDTHETGSKAALMGGTTTYIEMCCPSRNDDALEGYQLWKSKAEGNSYCDY
TFHMAVSKFDEKTEGQLREIVADGISSFKIFLSYKNFFGVDDGEMYQTLRLAKELGVIVT
AHCENAELVGRLQQKLLSEGKTGPEWHEPSRPEAVEAEGTARFATFLETTGATGYVVHLS
CKPALDAAMAAKARGVPIYIESVIPHFLLDKTYAERGGVEAMKYIMSPPLRDKRNQKVLW
DALAQGFIDTVGTDHCPFDTEQKLLGKEAFTAIPNGIPAIEDRVNLLYTYGVSRGRLDIH
RFVDAASTKAAKLFGLFPRKGTIAVGSDADLVVYDPQYRGTISVKTQHVNNDYNGFEGFE
IDGRPSVVTVRGKVAVRDGQFVGEKGWGKLLRREPMYF

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Not Available

# Drug_Target_10_SwissProt_ID:
Q7SIE9

# Drug_Target_10_SwissProt_Name:
Q7SIE9_THESP

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
5.99

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
AE000512

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
TM_0306

# Drug_Target_11_Gene_Sequence:
>1350 bp
ATGATTTCTATGAAACCCCGTTACAAACCTGACTGGGAATCTCTGAGGGAACACACAGTA
CCGAAATGGTTCGACAAGGCGAAATTCGGGATCTTCATTCACTGGGGGATTTACTCTGTT
CCGGGATGGGCGACGCCCACCGGAGAACTCGGTAAAGTGCCGATGGATGCCTGGTTCTTC
CAGAATCCGTACGCAGAGTGGTACGAAAATTCCCTCAGGATCAAGGAGAGTCCCACCTGG
GAATACCACGTGAAGACCTACGGAGAAAATTTCGAGTACGAGAAGTTTGCGGATCTTTTC
ACCGCAGAGAAGTGGGATCCACAAGAGTGGGCTGATCTCTTCAAAAAAGCAGGAGCGAAG
TACGTGATACCGACAACGAAACACCACGATGGATTTTGTCTGTGGGGGACGAAATACACA
GATTTCAACTCCGTGAAGAGAGGACCGAAGAGAGATCTCGTAGGAGATCTTGCAAAAGCC
GTAAGAGAAGCAGGATTGAGATTTGGAGTGTACTACTCAGGAGGTCTGGACTGGCGCTTC
ACGACCGAGCCGATAAGATACCCCGAGGATCTCTCCTACATCAGGCCGAACACTTACGAG
TACGCAGATTATGCCTACAAACAGGTCATGGAACTTGTGGATCTGTACCTTCCCGACGTT
CTCTGGAACGACATGGGCTGGCCGGAGAAAGGAAAGGAAGACCTGAAGTATCTCTTCGCT
TACTACTACAACAAACATCCAGAAGGTTCTGTGAACGACAGGTGGGGAGTGCCGCACTGG
GATTTCAAAACGGCCGAGTACCACGTGAACTATCCGGGGGATCTGCCGGGCTACAAATGG
GAGTTTACGAGGGGAATAGGGCTCTCTTTTGGATACAACCGAAACGAGGGGCCGGAACAC
ATGCTCTCTGTTGAACAGCTCGTCTACACACTCGTGGACGTTGTGAGCAAGGGAGGAAAT
CTCCTTTTGAACGTTGGGCCAAAGGGTGACGGAACGATTCCGGATCTGCAAAAAGAAAGA
CTCCTGGGCCTTGGTGAATGGCTGAGAAAGTACGGAGATGCCATCTACGGTACTTCTGTC
TGGGAAAGGTGCTGTGCGAAGACTGAGGATGGAACAGAGATCAGGTTCACCAGAAAATGT
AACAGAATCTTTGTCATCTTTCTCGGTATCCCGACCGGAGAAAAAATTGTAATTGAGGAT
CTCAATCTATCAGCAGGGACAGTGAGACATTTCCTGACGGGGGAGAGATTGAGCTTCAAA
AATGTGGGAAAGAACCTGGAAATCACAGTACCCAAAAAGCTCCTTGAAACAGACAGCATA
ACACTCGTGTTGGAGGCGGTGGAAGAATGA

# Drug_Target_11_General_Function:
Involved in alpha-L-fucosidase activity

# Drug_Target_11_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
4264

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
52206

# Drug_Target_11_Name:
Alpha-L-fucosidase, putative

# Drug_Target_11_Number_of_Residues:
449

# Drug_Target_11_PDB_ID:
1ODU

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF01120	Alpha_L_fucos

# Drug_Target_11_Protein_Sequence:
>Alpha-L-fucosidase, putative
MISMKPRYKPDWESLREHTVPKWFDKAKFGIFIHWGIYSVPGWATPTGELGKVPMDAWFF
QNPYAEWYENSLRIKESPTWEYHVKTYGENFEYEKFADLFTAEKWDPQEWADLFKKAGAK
YVIPTTKHHDGFCLWGTKYTDFNSVKRGPKRDLVGDLAKAVREAGLRFGVYYSGGLDWRF
TTEPIRYPEDLSYIRPNTYEYADYAYKQVMELVDLYLPDVLWNDMGWPEKGKEDLKYLFA
YYYNKHPEGSVNDRWGVPHWDFKTAEYHVNYPGDLPGYKWEFTRGIGLSFGYNRNEGPEH
MLSVEQLVYTLVDVVSKGGNLLLNVGPKGDGTIPDLQKERLLGLGEWLRKYGDAIYGTSV
WERCCAKTEDGTEIRFTRKCNRIFVIFLGIPTGEKIVIEDLNLSAGTVRHFLTGERLSFK
NVGKNLEITVPKKLLETDSITLVLEAVEE

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
Q9WYE2

# Drug_Target_11_SwissProt_Name:
Q9WYE2_THEMA

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
6.05

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasmic

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
U37105

# Drug_Target_12_GenBank_ID_Protein:
1019897

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
bla

# Drug_Target_12_Gene_Sequence:
>801 bp
ATGAAAACATTTGCCGCATATGTAATTATCGCGTGTCTTTCGAGTACGGCATTAGCTGGT
TCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTC
TTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCA
AAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAACGCAATTATCGGCCTAGAAACT
GGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAG
CAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTT
CAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCC
TATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAAGGCCAGCTTAGA
ATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCA
TCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATAT
CTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCA
TGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGAT
ATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGT
GAGGGCATCATTGGTGGCTAA

# Drug_Target_12_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_12_General_References:
11188693	Maveyraud L, Golemi D, Kotra LP, Tranier S, Vakulenko S, Mobashery S, Samama JP: Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure. 2000 Dec 15;8(12):1289-98.
3126705	Huovinen P, Huovinen S, Jacoby GA: Sequence of PSE-2 beta-lactamase. Antimicrob Agents Chemother. 1988 Jan;32(1):134-6.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
2340

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
29507

# Drug_Target_12_Name:
Beta-lactamase PSE-2

# Drug_Target_12_Number_of_Residues:
266

# Drug_Target_12_PDB_ID:
1K6R

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00905	Transpeptidase

# Drug_Target_12_Protein_Sequence:
>Beta-lactamase PSE-2 precursor
MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARAS
KEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVF
QQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSA
SKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMD
IDNESKLPLRKSIPTKIMESEGIIGG

# Drug_Target_12_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_12_Signals:
1-20

# Drug_Target_12_Specific_Function:
Hydrolyzes both carbenicillin and oxacillin

# Drug_Target_12_SwissProt_ID:
P14489

# Drug_Target_12_SwissProt_Name:
BLO10_PSEAE

# Drug_Target_12_Synonyms:
Beta lactamase OXA-10
Beta-lactamase PSE-2 precursor
EC 3.5.2.6

# Drug_Target_12_Theoretical_pI:
8.03

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasm

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
X51584

# Drug_Target_13_GenBank_ID_Protein:
42060

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
murD

# Drug_Target_13_Gene_Sequence:
>1317 bp
ATGGCTGATTATCAGGGTAAAAATGTCGTCATTATCGGCCTGGGCCTCACCGGGCTTTCC
TGCGTGGACTTTTTCCTCGCTCGCGGTGTGACGCCGCGCGTTATGGATACGCGTATGACA
CCGCCTGGCCTGGATAAATTACCCGAAGCCGTAGAACGCCACACGGGCAGTCTGAATGAT
GAATGGCTGATGGCGGCAGATCTGATTGTCGCCAGTCCCGGTATTGCACTGGCGCATCCA
TCCTTAAGCGCTGCCGCTGATGCCGGAATCGAAATCGTTGGCGATATCGAGCTGTTCTGT
CGCGAAGCACAAGCACCGATTGTGGCGATTACCGGTTCTAACGGCAAAAGCACGGTCACC
ACGCTAGTGGGTGAAATGGCGAAAGCGGCGGGGGTTAACGTTGGTGTGGGTGGCAATATT
GGCCTGCCTGCGTTGATGCTACTGGATGATGAGTGTGAACTGTACGTGCTGGAACTGTCG
AGCTTCCAGCTGGAAACCACCTCCAGCTTACAGGCGGTAGCAGCGACCATTCTGAACGTG
ACTGAAGATCATATGGATCGCTATCCGTTTGGTTTACAACAGTATCGTGCAGCAAAACTG
CGCATTTACGAAAACGCGAAAGTTTGCGTGGTTAATGCTGATGATGCCTTAACAATGCCG
ATTCGCGGTGCGGATGAACGCTGCGTCAGCTTTGGCGTCAACATGGGTGACTATCACCTG
AATCATCAGCAGGGCGAAACCTGGCTGCGGGTTAAAGGCGAGAAAGTGCTGAATGTGAAA
GAGATGAAACTTTCCGGGCAGCATAACTACACCAATGCGCTGGCGGCGCTGGCGCTGGCA
GATGCTGCAGGGTTACCGCGTGCCAGCAGCCTGAAAGCGTTAACCACATTCACTGGTCTG
CCGCATCGCTTTGAAGTTGTGCTGGAGCATAACGGCGTACGTTGGATTAACGATTCGAAA
GCGACCAACGTCGGCAGTACGGAAGCGGCGCTGAATGGCCTGCACGTAGACGGCACACTG
CATTTGTTGCTGGGTGGCGATGGTAAATCGGCGGACTTTAGCCCACTGGCGCGTTACCTG
AATGGCGATAACGTACGTCTGTATTGTTTCGGTCGTGACGGCGCGCAGCTGGCGGCGCTA
CGCCCGGAAGTGGCAGAACAAACCGAAACTATGGAACAGGCGATGCGCTTGCTGGCTCCG
CGTGTTCAGCCGGGCGATATGGTTCTGCTCTCCCCAGCCTGTGCCAGCCTTGATCAGTTC
AAGAACTTTGAACAACGAGGCAATGAGTTTGCCCGTCTGGCGAAGGAGTTAGGTTGA

# Drug_Target_13_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_13_General_References:
10966819	Bertrand JA, Fanchon E, Martin L, Chantalat L, Auger G, Blanot D, van Heijenoort J, Dideberg O: "Open" structures of MurD: domain movements and structural similarities with folylpolyglutamate synthetase. J Mol Biol. 2000 Sep 1;301(5):1257-66.
1630901	Yura T, Mori H, Nagai H, Nagata T, Ishihama A, Fujita N, Isono K, Mizobuchi K, Nakata A: Systematic sequencing of the Escherichia coli genome: analysis of the 0-2.4 min region. Nucleic Acids Res. 1992 Jul 11;20(13):3305-8.
1765076	Pratviel-Sosa F, Mengin-Lecreulx D, van Heijenoort J: Over-production, purification and properties of the uridine diphosphate N-acetylmuramoyl-L-alanine:D-glutamate ligase from Escherichia coli. Eur J Biochem. 1991 Dec 18;202(3):1169-76.
2129548	Mengin-Lecreulx D, van Heijenoort J: Nucleotide sequence of the murD gene encoding the UDP-MurNAc-L-Ala-D-Glu synthetase of Escherichia coli. Nucleic Acids Res. 1990 Jan 11;18(1):183.
2179861	Ikeda M, Wachi M, Ishino F, Matsuhashi M: Nucleotide sequence involving murD and an open reading frame ORF-Y spacing murF and ftsW in Escherichia coli. Nucleic Acids Res. 1990 Feb 25;18(4):1058.
2509435	Ikeda M, Sato T, Wachi M, Jung HK, Ishino F, Kobayashi Y, Matsuhashi M: Structural similarity among Escherichia coli FtsW and RodA proteins and Bacillus subtilis SpoVE protein, which function in cell division, cell elongation, and spore formation, respectively. J Bacteriol. 1989 Nov;171(11):6375-8.
9218784	Bertrand JA, Auger G, Fanchon E, Martin L, Blanot D, van Heijenoort J, Dideberg O: Crystal structure of UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase from Escherichia coli. EMBO J. 1997 Jun 16;16(12):3416-25.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
2317

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
46974

# Drug_Target_13_Name:
UDP-N-acetylmuramoylalanine--D-glutamate ligase

# Drug_Target_13_Number_of_Residues:
438

# Drug_Target_13_PDB_ID:
1EEH

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_13_Protein_Sequence:
>UDP-N-acetylmuramoylalanine--D-glutamate ligase
MADYQGKNVVIIGLGLTGLSCVDFFLARGVTPRVMDTRMTPPGLDKLPEAVERHTGSLND
EWLMAADLIVASPGIALAHPSLSAAADAGIEIVGDIELFCREAQAPIVAITGSNGKSTVT
TLVGEMAKAAGVNVGVGGNIGLPALMLLDDECELYVLELSSFQLETTSSLQAVAATILNV
TEDHMDRYPFGLQQYRAAKLRIYENAKVCVVNADDALTMPIRGADERCVSFGVNMGDYHL
NHQQGETWLRVKGEKVLNVKEMKLSGQHNYTNALAALALADAAGLPRASSLKALTTFTGL
PHRFEVVLEHNGVRWINDSKATNVGSTEAALNGLHVDGTLHLLLGGDGKSADFSPLARYL
NGDNVRLYCFGRDGAQLAALRPEVAEQTETMEQAMRLLAPRVQPGDMVLLSPACASLDQF
KNFEQRGNEFARLAKELG

# Drug_Target_13_Reaction:
ATP + UDP-N-acetylmuramoyl-L-alanine + D-glutamate = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-glutamate

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Cell wall formation. Catalyzes the addition of glutamate to the nucleotide precursor UDP-N-acetylmuramoyl-L-alanine (UMA)

# Drug_Target_13_SwissProt_ID:
P14900

# Drug_Target_13_SwissProt_Name:
MURD_ECOLI

# Drug_Target_13_Synonyms:
D-glutamic acid- adding enzyme
EC 6.3.2.9
UDP-N- acetylmuramoyl-L-alanyl-D-glutamate synthetase

# Drug_Target_13_Theoretical_pI:
4.96

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
M19142

# Drug_Target_14_GenBank_ID_Protein:
142467

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
alr

# Drug_Target_14_Gene_Sequence:
>1161 bp
ATGAACGACTTTCATCGCGATACGTGGGCGGAAGTGGATTTGGACGCCATTTACGACAAT
GTGGAGAATTTGCGCCGTTTGCTGCCGGACGACACGCACATTATGGCGGTCGTGAAAGCG
AACGCCTATGGACATGGGGATGTGCAGGTGGCAAGGACAGCGCTCGAACGGGGGCCTCCG
CCTGCGGTTGCCTTTTTGGATGAGGCGCTCGCTTTAAGGGAAAAAGGAATCGAAGCGCCG
ATTCTAGTTCTCGGGGCTTCCCGTCCAGCTGATGCGGCGCTGGCCGCCCAGCAGCGCATT
GCCCTGACCGTGTTCCGCTCCGACTGGTTGGAAGAAGCGTCCGCCCTTTACAGCGGCCCT
TTTCCTATTCATTTCCATTTGAAAATGGACACCGGCATGGGACGGCTTGGAGTGAAAGAC
GAGGAAGAGACGAAACGAATCGTAGCGCTGATTGAGCGCCATCCGCATTTTGTGCTTGAA
GGGTTGTACACGCATTTTGCGACTGCGGATGAGGTGAACACCGATTATTTTTCCTATCAG
TATACCCGTTTTTTGCACATGCTCGAATGGCTGCCGTCGCGCCCGCCGCTCGTCCATTGC
GCCAACAGCGCAGCGTCGCTCCGTTTCCCTGACCGGACGTTCAATATGGTCCGCTTCGGC
ATTGCCATGTATGGGCTTGCCCCGTCGCCCGGCATCAAGCCGCTGCTGCCGTATCCATTA
AAAGAAGCATTTTCGCTCCATAGCCGCCTCGTACACGTCAAAAAACTGCAACCAGGCGAA
AAGGTGAGCTATGGTGCGACGTACACTGCGCAGACGGAGGAGTGGATCGGGACGATTCCG
ATCGGCTATGCGGACGGCGTCCGCCGCCTGCAGCACTTTCATGTCCTTGTTGACGGACAA
AAGGCGCCGATTGTCGGCCGCATTTGCATGGACCAGTGCATGATCCGCCTGCCTGGTCCG
CTGCCGGTCGGCACGAAGGTGACACTGATTGGTCGCCAAGGGGACGAGGTAATTTCCATT
GATGATGTCGCTCGCCATTTGGAAACGATCAACTACGAAGTGCCTTGCACGATCAGTTAT
CGAGTGCCCCGTATTTTTTTCCGCCATAAGCGTATAATGGAAGTGAGAAACGCCATTGGC
CGCGGGGAAAGCAGTGCATAA

# Drug_Target_14_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_14_General_References:
10079072	Morollo AA, Petsko GA, Ringe D: Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase. Biochemistry. 1999 Mar 16;38(11):3293-301.
10194319	Sun S, Toney MD: Evidence for a two-base mechanism involving tyrosine-265 from arginine-219 mutants of alanine racemase. Biochemistry. 1999 Mar 30;38(13):4058-65.
10502689	Watanabe A, Yoshimura T, Mikami B, Esaki N: Tyrosine 265 of alanine racemase serves as a base abstracting alpha-hydrogen from L-alanine: the counterpart residue to lysine 39 specific to D-alanine. J Biochem (Tokyo). 1999 Oct;126(4):781-6.
2496744	Faraci WS, Walsh CT: Mechanism of inactivation of alanine racemase by beta, beta, beta-trifluoroalanine. Biochemistry. 1989 Jan 24;28(2):431-7.
2835089	Tanizawa K, Ohshima A, Scheidegger A, Inagaki K, Tanaka H, Soda K: Thermostable alanine racemase from Bacillus stearothermophilus: DNA and protein sequence determination and secondary structure prediction. Biochemistry. 1988 Feb 23;27(4):1311-6.
3730360	Badet B, Inagaki K, Soda K, Walsh CT: Time-dependent inhibition of Bacillus stearothermophilus alanine racemase by (1-aminoethyl)phosphonate isomers by isomerization to noncovalent slowly dissociating enzyme-(1-aminoethyl)phosphonate complexes. Biochemistry. 1986 Jun 3;25(11):3275-82.
9063881	Shaw JP, Petsko GA, Ringe D: Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9-A resolution. Biochemistry. 1997 Feb 11;36(6):1329-42.
9671513	Stamper GF, Morollo AA, Ringe D: Reaction of alanine racemase with 1-aminoethylphosphonic acid forms a stable external aldimine. Biochemistry. 1998 Jul 21;37(29):10438-45.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
2453

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
43594

# Drug_Target_14_Name:
Alanine racemase

# Drug_Target_14_Number_of_Residues:
388

# Drug_Target_14_PDB_ID:
1NIU

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00842	Ala_racemase_C
PF01168	Ala_racemase_N

# Drug_Target_14_Protein_Sequence:
>Alanine racemase
MNDFHRDTWAEVDLDAIYDNVENLRRLLPDDTHIMAVVKANAYGHGDVQVARTALEAGAS
RLAVAFLDEALALREKGIEAPILVLGASRPADAALAAQQRIALTVFRSDWLEEASALYSG
PFPIHFHLKMDTGMGRLGVKDEEETKRIVALIERHPHFVLEGLYTHFATADEVNTDYFSY
QYTRFLHMLEWLPSRPPLVHCANSAASLRFPDRTFNMVRFGIAMYGLAPSPGIKPLLPYP
LKEAFSLHSRLVHVKKLQPGEKVSYGATYTAQTEEWIGTIPIGYADGWLRRLQHFHVLVD
GQKAPIVGRICMDQCMIRLPGPLPVGTKVTLIGRQGDEVISIDDVARHLETINYEVPCTI
SYRVPRIFFRHKRIMEVRNAIGRGESSA

# Drug_Target_14_Reaction:
L-alanine = D-alanine

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Provides the D-alanine required for cell wall biosynthesis

# Drug_Target_14_SwissProt_ID:
P10724

# Drug_Target_14_SwissProt_Name:
ALR_GEOSE

# Drug_Target_14_Synonyms:
EC 5.1.1.1

# Drug_Target_14_Theoretical_pI:
7.11

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
X55814

# Drug_Target_15_GenBank_ID_Protein:
296014

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
murE

# Drug_Target_15_Gene_Sequence:
>1488 bp
GTGGCAGATCGTAATTTGCGCGACCTTCTTGCTCCGTGGGTGCCAGACGCACCTTCGCGA
GCACTGCGAGAGATGACACTCGACAGCCGTGTGGCTGCGGCGGGCGATCTCTTTGTAGCT
GTAGTAGGTCATCAGGCGGACGGGCGTCGATATATCCCGCAGGCGATAGCGCAAGGTGTG
GCTGCCATTATTGCAGAGGCGAAAGATGAGGCGACCGATGGTGAAATCCGTGAAATGCAC
GGCGTACCGGTCATCTATCTCAGCCAGCTCAACGAGCGTTTATCTGCACTGGCGGGCCGC
TTTTACCATGAACCCTCTGACAATTTACGTCTCGTGGGCGTAACGGGCACCAACGGCAAA
ACCACGACTACCCAGCTGTTGGCGCAGTGGAGCCAACTGCTTGGCGAAATCAGCGCGGTA
ATGGGCACCGTTGGTAACGGCCTGCTGGGGAAAGTGATCCCGACAGAAAATACAACCGGT
TCGGCAGTCGATGTTCAGCATGAGCTGGCGGGGCTGGTGGATCAGGGCGCGACGTTTTGC
GCAATGGAAGTTTCCTCCCACGGGCTGGTACAGCACCGTGTGGCGGCATTGAAATTTGCG
GCGTCGGTCTTTACCAACTTAAGCCGCGATCACCTTGATTATCATGGTGATATGGAACAC
TACGAAGCCGCGAAATGGCTGCTTTATTCTGAGCATCATTGCGGTCAGGCGATTATTAAC
GCCGACGATGAAGTGGGCCGCCGCTGGCTGGCAAAACTGCCGGACGCGGTTGCGGTATCA
ATGGAAGATCATATTAATCCGAACTGTCACGGACGCTGGTTGAAAGCGACCGAAGTGAAC
TATCACGACAGCGGTGCGACGATTCGCTTTAGCTCAAGTTGGGGCGATGGCGAAATTGAA
AGCCATCTGATGGGCGCTTTTAACGTCAGCAACCTGCTGCTCGCGCTGGCGACACTGTTG
GCACTCGGCTATCCACTGGCTGATCTGCTGAAAACCGCCGCGCGTCTGCAACCGGTTTGC
GGACGTATGGAAGTGTTCACTGCGCCAGGCAAACCGACGGTGGTGGTGGATTACGCGCAT
ACGCCGGATGCACTGGAAAAAGCCTTACAGGCGGCGCGTCTGCACTGTGCGGGCAAGCTG
TGGTGTGTCTTTGGCTGTGGTGGCGATCGCGATAAAGGTAAGCGTCCACTGATGGGCGCA
ATTGCCGAAGAGTTTGCTGACGTGGCGGTGGTGACGGACGATAACCCGCGTACCGAAGAA
CCGCGTGCCATCATCAACGATATTCTGGCGGGAATGTTAGATGCCGGACATGCCAAAGTG
ATGGAAGGCCGTGCTGAAGCGGTGACTTGCGCCGTTATGCAGGCTAAAGAGAATGATGTG
GTACTGGTCGCGGGCAAAGGCCATGAAGATTACCAGATTGTTGGCAATCAGCGTCTGGAC
TACTCCGATCGCGTCACGGTGGCGCGTCTGCTGGGGGTGATTGCATGA

# Drug_Target_15_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_15_General_References:
1630901	Yura T, Mori H, Nagai H, Nagata T, Ishihama A, Fujita N, Isono K, Mizobuchi K, Nakata A: Systematic sequencing of the Escherichia coli genome: analysis of the 0-2.4 min region. Nucleic Acids Res. 1992 Jul 11;20(13):3305-8.
2198024	Michaud C, Parquet C, Flouret B, Blanot D, van Heijenoort J: Revised interpretation of the sequence containing the murE gene encoding the UDP-N-acetylmuramyl-tripeptide synthetase of Escherichia coli. Biochem J. 1990 Jul 1;269(1):277-8.
2269304	Michaud C, Mengin-Lecreulx D, van Heijenoort J, Blanot D: Over-production, purification and properties of the uridine-diphosphate-N-acetylmuramoyl-L-alanyl-D-glutamate: meso-2,6-diaminopimelate ligase from Escherichia coli. Eur J Biochem. 1990 Dec 27;194(3):853-61.
2692800	Tao JS, Ishiguro EE: Nucleotide sequence of the murE gene of Escherichia coli. Can J Microbiol. 1989 Nov;35(11):1051-4.
9166795	Eveland SS, Pompliano DL, Anderson MS: Conditionally lethal Escherichia coli murein mutants contain point defects that map to regions conserved among murein and folyl poly-gamma-glutamate ligases: identification of a ligase superfamily. Biochemistry. 1997 May 20;36(20):6223-9.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
2801

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
53344

# Drug_Target_15_Name:
UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase

# Drug_Target_15_Number_of_Residues:
495

# Drug_Target_15_PDB_ID:
1E8C

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF01225	Mur_ligase
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_15_Protein_Sequence:
>UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase
MADRNLRDLLAPWVPDAPSRALREMTLDSRVAAAGDLFVAVVGHQADGRRYIPQAIAQGV
AAIIAEAKDEATDGEIREMHGVPVIYLSQLNERLSALAGRFYHEPSDNLRLVGVTGTNGK
TTTTQLLAQWSQLLGEISAVMGTVGNGLLGKVIPTENTTGSAVDVQHELAGLVDQGATFC
AMEVSSHGLVQHRVAALKFAASVFTNLSRDHLDYHGDMEHYEAAKWLLYSEHHCGQAIIN
ADDEVGRRWLAKLPDAVAVSMEDHINPNCHGRWLKATEVNYHDSGATIRFSSSWGDGEIE
SHLMGAFNVSNLLLALATLLALGYPLADLLKTAARLQPVCGRMEVFTAPGKPTVVVDYAH
TPDALEKALQAARLHCAGKLWCVFGCGGDRDKGKRPLMGAIAEEFADVAVVTDDNPRTEE
PRAIINDILAGMLDAGHAKVMEGRAEAVTCAVMQAKENDVVLVAGKGHEDYQIVGNQRLD
YSDRVTVARLLGVIA

# Drug_Target_15_Reaction:
ATP + UDP-N-acetylmuramoyl-L-alanyl-D-glutamate + meso-2,6-diaminoheptanedioate = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diamino- heptanedioate

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Cell wall formation. Diaminopimelic acid adding enzyme

# Drug_Target_15_SwissProt_ID:
P22188

# Drug_Target_15_SwissProt_Name:
MURE_ECOLI

# Drug_Target_15_Synonyms:
EC 6.3.2.13
Meso- diaminopimelate-adding enzyme
UDP-MurNAc-tripeptide synthetase
UDP-N-acetylmuramyl-tripeptide synthetase

# Drug_Target_15_Theoretical_pI:
5.53

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Cell membrane
peripheral membrane protein

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
M29593

# Drug_Target_16_GenBank_ID_Protein:
148713

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
opd

# Drug_Target_16_Gene_Sequence:
>1098 bp
ATGCAAACGAGAAGGGTTGTGCTCAAGTCTGCGGCCGCCGCAGGAACTCTGCTCGGCGGC
CTGGCTGGGTGCGCGAGCGTGGCTGGATCGATCGGCACAGGCGATCGGATCAATACCGTG
CGCGGTCCTATCACAATCTCTGAAGCGGGTTTCACACTGACTCACGAGCACATCTGCGGC
AGCTCGGCAGGATTCTTGCGTGCTTGGCCAGAGTTCTTCGGTAGCCGCAAAGCTCTAGCG
GAAAAGGCTGTGAGAGGATTGCGCCGCGCCAGAGCGGCTGGCGTGCGAACGATTGTCGAT
GTGTCGACTTTCGATATCGGTCGCGACGTCAGTTTATTGGCCGAGGTTTCGCGGGCTGCC
GACGTTCATATCGTGGCGGCGACCGGCTTGTGGTTCGACCCGCCACTTTCGATGCGATTG
AGGAGTGTAGAGGAACTCACACAGTTCTTCCTGCGTGAGATTCAATATGGCATCGAAGAC
ACCGGAATTAGGGCGGGCATTATCAAGGTCGCGACCACAGGCAAGGCGACCCCCTTTCAG
GAGTTAGTGTTAAAGGCGGCCGCCCGGGCCAGCTTGGCCACCGGTGTTCCGGTAACCACT
CACACGGCAGCAAGTCAGCGCGATGGTGAGCAGCAGGCCGCCATTTTTGAGTCCGAAGGC
TTGAGCCCCTCACGGGTTTGTATTGGTCACAGCGATGATACTGACGATTTGAGCTATCTC
ACCGCCCTCGCTGCGCGCGGATACCTCATCGGTCTAGACCACATCCCGCACAGTGCGATT
GGTCTAGAAGATAATGCGAGTGCATCAGCCCTCCTGGGCATCCGTTCGTGGCAAACACGG
GCTCTCTTGATCAAGGCGCTCATCGACCAAGGCTACATGAAACAAATCCTCGTTTCGAAT
GACTGGCTGTTCGGGTTTTCGAGCTATGTCACCAACATCATGGACGTGATGGATCGCGTG
AACCCCGACGGGATGGCCTTCATTCCACTGAGAGTGATCCCATTCCTACGAGAGAAGGGC
GTCCCACAGGAAACGCTGGCAGGCATCACTGTGACTAACCCGGCGCGGTTCTTGTCACCG
ACCTTGCGGGCGTCATGA

# Drug_Target_16_General_Function:
Involved in zinc ion binding

# Drug_Target_16_General_References:
2556372	Mulbry WW, Karns JS: Parathion hydrolase specified by the Flavobacterium opd gene: relationship between the gene and protein. J Bacteriol. 1989 Dec;171(12):6740-6.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
2796

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
39004

# Drug_Target_16_Name:
Parathion hydrolase

# Drug_Target_16_Number_of_Residues:
365

# Drug_Target_16_PDB_ID:
1PSC

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF02126	PTE

# Drug_Target_16_Protein_Sequence:
>Parathion hydrolase precursor
MQTRRVVLKSAAAAGTLLGGLAGCASVAGSIGTGDRINTVRGPITISEAGFTLTHEHICG
SSAGFLRAWPEFFGSRKALAEKAVRGLRRARAAGVRTIVDVSTFDIGRDVSLLAEVSRAA
DVHIVAATGLWFDPPLSMRLRSVEELTQFFLREIQYGIEDTGIRAGIIKVATTGKATPFQ
ELVLKAAARASLATGVPVTTHTAASQRDGEQQAAIFESEGLSPSRVCIGHSDDTDDLSYL
TALAARGYLIGLDHIPHSAIGLEDNASASALLGIRSWQTRALLIKALIDQGYMKQILVSN
DWLFGFSSYVTNIMDVMDRVNPDGMAFIPLRVIPFLREKGVPQETLAGITVTNPARFLSP
TLRAS

# Drug_Target_16_Reaction:
an aryl dialkyl phosphate + H2O = dialkyl phosphate + an aryl alcohol

# Drug_Target_16_Signals:
1-29

# Drug_Target_16_Specific_Function:
Has an unusual substrate specificity for synthetic organophosphate triesters and phosphorofluoridates. All of the phosphate triesters found to be substrates are synthetic compounds. The identity of any naturally occurring substrate for the enzyme is unknown. Has no detectable activity with phosphate monoesters or diesters and no activity as an esterase or protease. It catalyzes the hydrolysis of the insecticide paraoxon at a rate approaching the diffusion limit and thus appears to be optimally evolved for utilizing this synthetic substrate

# Drug_Target_16_SwissProt_ID:
P0A433

# Drug_Target_16_SwissProt_Name:
OPD_FLAS2

# Drug_Target_16_Synonyms:
EC 3.1.8.1
PTE
Parathion hydrolase precursor
Phosphotriesterase

# Drug_Target_16_Theoretical_pI:
8.48

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
J05221

# Drug_Target_17_GenBank_ID_Protein:
149542

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
fgs

# Drug_Target_17_Gene_Sequence:
>1287 bp
ATGAATTACACAGAAACGGTTGCCTACATTCATTCTTTTCCGCGTTTGGCCAAGACCGGT
GACCATCGGCGGATTTTAACGTTATTACATGCACTCGGCAATCCGCAGCAACAAGGGCGG
TATATTCACGTGACTGGTACTAATGGAAAAGGCTCAGCCGCTAATGCGATTGCACATGTC
CTTGAGGCAAGCGGTTTGACAGTCGGGTTATATACCTCGCCGTTTATCATGCGGTTTAAT
GAACGGATCATGATTGACCATGAACCGATTCCGGATGCTGCGTTAGTCAATGCGGTTGCG
TTTGTCAGGGCTGCACTGGAGCGGCTTCAGCAGCAACAAGCTGATTTTAACGTGACGGAA
TTTGAATTCATTACCGCGCTGGGCTATTGGTATTTTCGTCAGCGTCAGGTTGATGTTGCG
GTGATTGAAGTCGGTATTGGCGGCGACACGGATTCGACCAATGTCATCACGCCGGTTGTC
AGTGTTTTGACCGAGGTTGCTTTAGATCACCAGAAGTTGCTGGGGCATACGATTACGGCG
ATTGCCAAGCATAAGGCCGGTATTATCAAACGGGGTATTCCGGTTGTAACCGGTAACTTG
GTGCCGGATGCTGCTGCCGTTGTCGCAGCCAAGGTCGCGACAACAGGGAGTCAATGGTTG
CGTTTTGACCGCGATTTTTCGGTTCCTAAGGCTAAGCTTCACGGTTGGGGCCAACGGTTT
ACTTATGAAGACCAAGATGGACGTATTAGTGATTTGGAGGTGCCGTTGGTTGGCGATTAC
CAGCAACGTAATATGGCAATTGCGATTCAAACGGCAAAAGTGTATGCCAAGCAGACAGAA
TGGCCTTTGACGCCCCAGAATATTCGCCAAGGGCTTGCTGCCAGTCATTGGCCAGCCCGA
CTCGAAAAGATAAGTGATACGCCTTTGATCGTCATTGACGGGGCGCACAATCCGGATGGC
ATCAATGGTTTGATTACGGCGCTAAAGCAACTTTTTTCCCAACCCATTACTGTTATTGCC
GGCATCTTGGCGGATAAAGACTATGCGGCGATGGCGGATAGGCTGACCGCGGCATTTTCC
ACGGTTTATCTGGTTCCGGTGCCGGGGACGCCGCGCGCCTTGCCTGAGGCTGGTTATGAG
GCGCTGCACGAAGGTCGGTTAAAGGATTCGTGGCAGGAAGCATTGGCGGCGAGTCTTAAT
GATGTGCCGGATCAGCCGATTGTGATCACCGGTTCGCTGTATTTAGCCTCAGCTGTTCGT
CAAACTTTATTAGGGGGAAAATCATGA

# Drug_Target_17_General_Function:
Coenzyme transport and metabolism

# Drug_Target_17_General_References:
2105929	Toy J, Bognar AL: Cloning and expression of the gene encoding Lactobacillus casei folylpoly-gamma-glutamate synthetase in Escherichia coli and determination of its primary structure. J Biol Chem. 1990 Feb 15;265(5):2492-9.
9618466	Sun X, Bognar AL, Baker EN, Smith CA: Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6647-52.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
2717

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
46590

# Drug_Target_17_Name:
Folylpolyglutamate synthase

# Drug_Target_17_Number_of_Residues:
428

# Drug_Target_17_PDB_ID:
1FGS

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_17_Protein_Sequence:
>Folylpolyglutamate synthase
MNYTETVAYIHSFPRLAKTGDHRRILTLLHALGNPQQQGRYIHVTGTNGKGSAANAIAHV
LEASGLTVGLYTSPFIMRFNERIMIDHEPIPDAALVNAVAFVRAALERLQQQQADFNVTE
FEFITALGYWYFRQRQVDVAVIEVGIGGDTDSTNVITPVVSVLTEVALDHQKLLGHTITA
IAKHKAGIIKRGIPVVTGNLVPDAAAVVAAKVATTGSQWLRFDRDFSVPKAKLHGWGQRF
TYEDQDGRISDLEVPLVGDYQQRNMAIAIQTAKVYAKQTEWPLTPQNIRQGLAASHWPAR
LEKISDTPLIVIDGAHNPDGINGLITALKQLFSQPITVIAGILADKDYAAMADRLTAAFS
TVYLVPVPGTPRALPEAGYEALHEGRLKDSWQEALAASLNDVPDQPIVITGSLYLASAVR
QTLLGGKS

# Drug_Target_17_Reaction:
ATP + tetrahydropteroyl-[gamma-Glu]n + L-glutamate = ADP + phosphate + tetrahydropteroyl-[gamma-Glu]n+1

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Conversion of folates to polyglutamate derivatives. It preferes 5,10-methylenetetrahydrofolate, rather than 10- formyltetrahydrofolate as folate substrate

# Drug_Target_17_SwissProt_ID:
P15925

# Drug_Target_17_SwissProt_Name:
FOLC_LACCA

# Drug_Target_17_Synonyms:
EC 6.3.2.17
FPGS
Folylpoly-gamma-glutamate synthetase
Tetrahydrofolate synthase
Tetrahydrofolylpolyglutamate synthase

# Drug_Target_17_Theoretical_pI:
7.02

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Cytoplasmic

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
X04469

# Drug_Target_18_GenBank_ID_Protein:
42607

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
pyrC

# Drug_Target_18_Gene_Sequence:
>1047 bp
ATGACTGCACCATCCCAGGTATTAAAGATCCGCCGCCCAGACGACTGGCACCTTCACCTC
CGCGATGGCGACATGTTAAAAACTGTCGTGCCATATACCAGCGAAATTTATGGACGGGCT
ATCGTAATGCCCAATCTGGCTCCGCCCGTGACCACCGTTGAGGCTGCCGTGGCGTATCGC
CAGCGTATTCTTGACGCCGTACCTGCCGGGCACGATTTCACCCCATTGATGACCTGTTAT
TTAACAGATTCGCTGGATCCTAATGAGCTGGAGCGCGGATTTAACGAAGGCGTGTTCACC
GCTGCAAAACTTTACCCGGCAAACGCAACCACTAACTCCAGCCACGGCGTGACGTCAATT
GACGCAATCATGCCGGTACTTGAGCGCATGGAAAAAATCGGTATGCCGCTACTGGTGCAT
GGTGAAGTGACACATGCAGATATCGACATTTTTGATCGTGAAGCGCGCTTTATAGAAAGC
GTGATGGAACCTCTGCGCCAGCGCCTGACTGCGCTGAAAGTCGTTTTTGAGCACATCACC
ACCAAAGATGCTGCCGACTATGTCCGTGACGGAAATGAACGGCTGGCTGCCACCATCACT
CCGCAGCATCTGATGTTTAACCGCAACCATATGCTGGTTGGAGGCGTGCGTCCGCACCTG
TATTGTCTACCCATCCTCAAACGTAATATTCACCAACAGGCATTGCGTGAACTGGTCGCC
AGCGGTTTTAATCGAGTATTCCTCGGTACGGATTCTGCGCCACATGCACGTCATCGCAAA
GAGAGCAGTTGCGGCTGCGCGGGCTGCTTCAACGCCCCAACCGCGCTGGGCAGTTACGCT
ACCGTCTTTGAAGAAATGAATGCTTTGCAGCACTTTGAAGCATTCTGTTCTGTAAACGGC
CCGCAGTTCTATGGGTTGCCGGTCAACGACACATTCATCGAACTGGTACGTGAAGAGCAA
CAGGTTGCTGAAAGCATCGCACTGACTGATGACACGCTGGTGCCATTCCTCGCCGGGGAA
ACGGTACGCTGGTCCGTTAAACAATAA

# Drug_Target_18_General_Function:
Nucleotide transport and metabolism

# Drug_Target_18_General_References:
11401542	Thoden JB, Phillips GN Jr, Neal TM, Raushel FM, Holden HM: Molecular structure of dihydroorotase: a paradigm for catalysis through the use of a binuclear metal center. Biochemistry. 2001 Jun 19;40(24):6989-97.
1671037	Brown DC, Collins KD: Dihydroorotase from Escherichia coli. Substitution of Co(II) for the active site Zn(II). J Biol Chem. 1991 Jan 25;266(3):1597-604.
2876892	Backstrom D, Sjoberg RM, Lundberg LG: Nucleotide sequence of the structural gene for dihydroorotase of Escherichia coli K12. Eur J Biochem. 1986 Oct 1;160(1):77-82.
2885307	Wilson HR, Chan PT, Turnbough CL Jr: Nucleotide sequence and expression of the pyrC gene of Escherichia coli K-12. J Bacteriol. 1987 Jul;169(7):3051-8.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
2646

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
38828

# Drug_Target_18_Name:
Dihydroorotase

# Drug_Target_18_Number_of_Residues:
348

# Drug_Target_18_PDB_ID:
1XGE

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_18_Protein_Sequence:
>Dihydroorotase
MTAPSQVLKIRRPDDWHLHLRDGDMLKTVVPYTSEIYGRAIVMPNLAPPVTTVEAAVAYR
QRILDAVPAGHDFTPLMTCYLTDSLDPNELERGFNEGVFTAAKLYPANATTNSSHGVTSI
DAIMPVLERMEKIGMPLLVHGEVTHADIDIFDREARFIESVMEPLRQRLTALKVVFEHIT
TKDAADYVRDGNERLAATITPQHLMFNRNHMLVGGVRPHLYCLPILKRNIHQQALRELVA
SGFNRVFLGTDSAPHARHRKESSCGCAGCFNAPTALGSYATVFEEMNALQHFEAFCSVNG
PQFYGLPVNDTFIELVREEQQVAESIALTDDTLVPFLAGETVRWSVKQ

# Drug_Target_18_Reaction:
(S)-dihydroorotate + H2O = N-carbamoyl-L-aspartate

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
(S)-dihydroorotate + H(2)O = N-carbamoyl-L- aspartate

# Drug_Target_18_SwissProt_ID:
P05020

# Drug_Target_18_SwissProt_Name:
PYRC_ECOLI

# Drug_Target_18_Synonyms:
DHOase
EC 3.5.2.3

# Drug_Target_18_Theoretical_pI:
6.14

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
CDK2

# Drug_Target_19_GenBank_ID_Gene:
X61622

# Drug_Target_19_GenBank_ID_Protein:
29849

# Drug_Target_19_GeneCard_ID:
CDK2

# Drug_Target_19_Gene_Name:
CDK2

# Drug_Target_19_Gene_Sequence:
>897 bp
ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA
GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG
ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT
CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT
GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT
CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT
CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC
ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC
CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTCGAAATATTAT
TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG
GCCCTGTTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG
ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC
CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG
AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC
CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA

# Drug_Target_19_General_Function:
Involved in protein kinase activity

# Drug_Target_19_General_References:
1396589	Gu Y, Rosenblatt J, Morgan DO: Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992 Nov;11(11):3995-4005.
1653904	Tsai LH, Harlow E, Meyerson M: Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature. 1991 Sep 12;353(6340):174-7.
1714386	Elledge SJ, Spottswood MR: A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Eg1. EMBO J. 1991 Sep;10(9):2653-9.
1717994	Ninomiya-Tsuji J, Nomoto S, Yasuda H, Reed SI, Matsumoto K: Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9006-10.
7630397	Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 Jul 27;376(6538):313-20.
8510751	De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH: Crystal structure of cyclin-dependent kinase 2. Nature. 1993 Jun 17;363(6430):595-602.
8601310	Bourne Y, Watson MH, Hickey MJ, Holmes W, Rocque W, Reed SI, Tainer JA: Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell. 1996 Mar 22;84(6):863-74.
8610110	De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40.
8684460	Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature. 1996 Jul 25;382(6589):325-31.
8756328	Russo AA, Jeffrey PD, Pavletich NP: Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol. 1996 Aug;3(8):696-700.
8917641	Schulze-Gahmen U, De Bondt HL, Kim SH: High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J Med Chem. 1996 Nov 8;39(23):4540-6.
9334743	Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA: Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 1997 Oct;4(10):796-801.
9677190	Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.

# Drug_Target_19_HGNC_ID:
HGNC:1771

# Drug_Target_19_HPRD_ID:
00310

# Drug_Target_19_ID:
2240

# Drug_Target_19_Locus:
12q13

# Drug_Target_19_Molecular_Weight:
33930

# Drug_Target_19_Name:
Cell division protein kinase 2

# Drug_Target_19_Number_of_Residues:
298

# Drug_Target_19_PDB_ID:
1V1K

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_19_Protein_Sequence:
>Cell division protein kinase 2
MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNH
PNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHS
HRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYY
STAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF
PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL

# Drug_Target_19_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Probably involved in the control of the cell cycle. Interacts with cyclins A, B3, D, or E. Activity of CDK2 is maximal during S phase and G2

# Drug_Target_19_SwissProt_ID:
P24941

# Drug_Target_19_SwissProt_Name:
CDK2_HUMAN

# Drug_Target_19_Synonyms:
EC 2.7.11.22
p33 protein kinase

# Drug_Target_19_Theoretical_pI:
8.99

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF320814

# Drug_Target_1_GenBank_ID_Protein:
17224959

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
hyuA

# Drug_Target_1_Gene_Sequence:
>1374 bp
ATGGACATCATTATCAAAAACGGAACCATCGTGACCGCGGATGGCATTTCTCGCGCCGAT
CTCGGGATCAAGGATGGCAAGATCACCCAGATCGGCGGCGCGCTCGGCCCAGCGGAGCGG
ACGATCGACGCGGCCGGCCGCTACGTCTTTCCGGGCGGCATAGACGTTCACACGCATGTC
GAAACGGTCAGCTTCAACACGCAGTCGGCCGACACGTTCGCAACAGCGACGGTCGCGGCC
GCCTGTGGCGGAACGACAACCATCGTCGATTTCTGTCAGCAGGATCGCGGCCACAGCCTG
GCGGAAGCCGTCGCCAAGTGGGACGGTATGGCCGGCGGCAAGTCGGCGATCGATTACGGC
TACCACATCATCGTGCTCGACCCGACCGACAGCGTGATTGAGGAGCTGGAGGTGCTTCCC
GATCTTGGCATTACCTCCTTCAAGGTCTTCATGGCCTATCGCGGCATGAACATGATCGAC
GACGTGACGCTGCTGAAGACGCTCGACAAGGCGGTCAAGACCGGATCGCTCGTCATGGTG
CACGCGGAAAACGGCGACGCCGCCGACTATCTGCGCGACAAGTTCGTGGCCGAGGGCAAA
ACCGCGCCGATCTACCACGCGCTCAGCCGCCCGCCCCGGGTCGAAGCCGAGGCAACCGCG
CGGGCCCTCGCCCTGGCCGAAATCGTCAACGCCCCGATCTACATAGTCCATGTGACCTGC
GAGGAGTCCCTTGAGGAGGTGATGCGCGCAAAATCGCGAGGCGTCCGCGCTCTGGCGGAA
ACCTGCACGCATTACCTTTACCTCACCAAGGAAGACCTGGAGCGGCCGGATTTCGAAGGT
GCGAAATACGTTTTCACACCGCCGGCCCGCGCGAAGAAAGACCATGACGTTCTCTGGAAC
GCACTCAGAAACGGTGTGTTCGAAACGGTTTCCTCCGACCATTGCTCCTGGCTCTTCAAG
GGGCACAAGGACCGGGGCCGGAACGACTTTCGCGCCATCCCGAACGGCGCGCCGGGCGTC
GAGGAACGGTTGATGATGGTCTATCAGGGCGTCAACGAAGGCCGGATTTCCCTTACCCAG
TTCGTGGAACTGGTCGCCACGCGCCCGGCCAAGGTCTTCGGAATGTTTCCGCAAAAGGGG
ACGATCGCGGTCGGTTCGGACGCCGACATCGTCCTTTGGGACCCCGAGGCCGAAATGGTG
ATCGAACAGACCGCCATGCACAACGCCATGGATTACTCCTCCTACGAGGGACACAAGGTC
AAGGGCGTGCCGAAGACGGTGCTCCTGCGTGGCAAGGTTATCGTCGACGAAGGTTCCTAT
GTCGGCGAACCGACGGACGGGAAATTCCTGAAACGTCGCAAATACAAGCAGTAA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3145

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
49932

# Drug_Target_1_Name:
D-hydantoinase

# Drug_Target_1_Number_of_Residues:
457

# Drug_Target_1_PDB_ID:
1NFG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_1_Protein_Sequence:
>D-hydantoinase
MDIIIKNGTIVTADGISRADLGIKDGKITQIGGALGPAERTIDAAGRYVFPGGIDVHTHV
ETVSFNTQSADTFATATVAAACGGTTTIVDFCQQDRGHSLAEAVAKWDGMAGGKSAIDYG
YHIIVLDPTDSVIEELEVLPDLGITSFKVFMAYRGMNMIDDVTLLKTLDKAVKTGSLVMV
HAENGDAADYLRDKFVAEGKTAPIYHALSRPPRVEAEATARALALAEIVNAPIYIVHVTC
EESLEEVMRAKSRGVRALAETCTHYLYLTKEDLERPDFEGAKYVFTPPARAKKDHDVLWN
ALRNGVFETVSSDHCSWLFKGHKDRGRNDFRAIPNGAPGVEERLMMVYQGVNEGRISLTQ
FVELVATRPAKVFGMFPQKGTIAVGSDADIVLWDPEAEMVIEQTAMHNAMDYSSYEGHKV
KGVPKTVLLRGKVIVDEGSYVGEPTDGKFLKRRKYKQ

# Drug_Target_1_Reaction:
5,6-dihydrouracil + H2O = 3-ureidopropanoate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
5,6-dihydrouracil + H(2)O = 3- ureidopropanoate

# Drug_Target_1_SwissProt_ID:
Q8VTT5

# Drug_Target_1_SwissProt_Name:
HYDA_BURPI

# Drug_Target_1_Synonyms:
DHPase
Dihydropyrimidinase
EC 3.5.2.2

# Drug_Target_1_Theoretical_pI:
5.93

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
J02967

# Drug_Target_2_GenBank_ID_Protein:
152064

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
bla

# Drug_Target_2_Gene_Sequence:
>831 bp
ATGAAAAACACAATACATATCAACTTCGCTATTTTTTTAATAATTGCAAATATTATCTAC
AGCAGCGCCAGTGCATCAACAGATATCTCTACTGTTGCATCTCCATTATTTGAAGGAACT
GAAGGTTGTTTTTTACTTTACGATGCATCCACAAACGCTGAAATTGCTCAATTCAATAAA
GCAAAGTGTGCAACGCAAATGGCACCAGATTCAACTTTCAAGATCGCATTATCACTTATG
GCATTTGATGCGGAAATAATAGATCAGAAAACCATATTCAAATGGGATAAAACCCCCAAA
GGAATGGAGATCTGGAACAGCAATCATACACCAAAGACGTGGATGCAATTTTCTGTTGTT
TGGGTTTCGCAAGAAATAACCCAAAAAATTAGATTAAATAAAATCAAGAATTATCTCAAA
GATTTTGATTATGGAAATCAAGACTTCTCTGGAGATAAAGAAAGAAACAACGGATTAACA
GAAGCATGGCTCGAAAGTAGCTTAAAAATTTCACCAGAAGAACAAATTCAATTCCTGCGT
AAAATTATTAATCACAATCTCCCAGTTAAAAACTCAGCCATAGAAAACACCATAGAGAAC
ATGTATCTACAAGATCTGGATAATAGTACAAAACTGTATGGGAAAACTGGTGCAGGATTC
ACAGCAAATAGAACCTTACAAAACGGATGGTTTGAAGGGTTTATTATAAGCAAATCAGGA
CATAAATATGTTTTTGTGTCCGCACTTACAGGAAACTTGGGGTCGAATTTAACATCAAGC
ATAAAAGCCAAGAAAAATGCGATCACCATTCTAAACACACTAAATTTATAA

# Drug_Target_2_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_2_General_References:
2823258	Ouellette M, Bissonnette L, Roy PH: Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7378-82.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3168

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
30980

# Drug_Target_2_Name:
Beta-lactamase OXA-1

# Drug_Target_2_Number_of_Residues:
276

# Drug_Target_2_PDB_ID:
1M6K

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00905	Transpeptidase

# Drug_Target_2_Protein_Sequence:
>Beta-lactamase OXA-1 precursor
MKNTIHINFAIFLIIANIIYSSASASTDISTVASPLFEGTEGCFLLYDASTNAEIAQFNK
AKCATQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKTPKGMEIWNSNHTPKTWMQFSVV
WVSQEITQKIRLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQIQFLR
KIINHNLPVKNSAIENTIENMYLQDLDNSTKLYGKTGAGFTANRTLQNGWFEGFIISKSG
HKYVFVSALTGNLGSNLTSSIKAKKNAITILNTLNL

# Drug_Target_2_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_2_Signals:
1-23

# Drug_Target_2_Specific_Function:
This is an oxacillin-hydrolyzing beta-lactamase

# Drug_Target_2_SwissProt_ID:
P13661

# Drug_Target_2_SwissProt_Name:
BLO1_ECOLX

# Drug_Target_2_Synonyms:
Beta-lactamase OXA-1 precursor
EC 3.5.2.6
Penicillinase

# Drug_Target_2_Theoretical_pI:
8.62

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
lhyD

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
9650283	May O, Siemann M, Pietzsch M, Kiess M, Mattes R, Syldatk C: Substrate-dependent enantioselectivity of a novel hydantoinase from Arthrobacter aurescens DSM 3745: purification and characterization as new member of cyclic amidases. J Biotechnol. 1998 Mar 26;61(1):1-13.
9687026	May O, Habenicht A, Mattes R, Syldatk C, Siemann M: Molecular evolution of hydantoinases. Biol Chem. 1998 Jun;379(6):743-7.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3230

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
49597

# Drug_Target_3_Name:
Non-ATP-dependent L-selective hydantoinase

# Drug_Target_3_Number_of_Residues:
458

# Drug_Target_3_PDB_ID:
1GKR

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_3_Protein_Sequence:
>Non-ATP-dependent L-selective hydantoinase
MFDVIVKNCRLVSSDGITEADILVKDGKVAAISADTSDVEASRTIDAGGKFVMPGVVDEH
VHIIDMDLKNRYGRFELDSESAAVGGITTIIEMPITFPPTTTLDAFLEKKKQAGQRLKVD
FALYGGGVPGNLPEIRKMHDAGAVGFKSMMAASVPGMFDAVSDGELFEIFQEIAACGSVI
VVHAENETIIQALQKQIKAAGGKDMAAYEASQPVFQENEAIQRALLLQKEAGCRLIVLHV
SNPDGVELIHQAQSEGQDVHCESGPQYLNITTDDAERIGPYMKVAPPVRSAEMNIRLWEQ
LENGLIDTLGSDHGGHPVEDKEPGWKDVWKAGNGALGLETSLPMMLTNGVNKGRLSLERL
VEVMCEKPAKLFGIYPQKGTLQVGSDADLLILDLDIDTKVDASQFRSLHKYSPFDGMPVT
GAPVLTMVRGTVVAEKGEVLVEQGFGQFVTRRNYEASK

# Drug_Target_3_Reaction:
5,6-dihydrouracil + H2O = 3-ureidopropanoate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Rather more predominant for the cleavage of aryl- than for alkyl-hydantoin derivatives. The stereoselectivity of this enzyme depends on the substrate used for bioconversion:strictly L-selective for the cleavage of D,L-5-indolylmethylhydantoin, but D-selective for the hydrolysis of D,L-methylthioethylhydantoin

# Drug_Target_3_SwissProt_ID:
P81006

# Drug_Target_3_SwissProt_Name:
HYDL_ARTAU

# Drug_Target_3_Synonyms:
EC 3.5.2.2

# Drug_Target_3_Theoretical_pI:
4.66

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
S73773

# Drug_Target_4_GenBank_ID_Protein:
688288

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
>1416 bp
ATGACAAAATTGATAAAAAATGGAACAATTGTCACCGCTACAGATATATATGAAGCCGAT
CTCCTCATTCAAGATGGGAAAATTGCAGTAATCGGGAGAAATTTAGATGAGAGCGGAGCG
GAAGTGATTGATGCCACAGGTTGTTATGTGTTTCCAGGAGGCATTGATCCGCACACCCAT
TTAGATATGCCGTTTGGCGGCACTGTGACAAAAGACGACTTTGAGTCGGGGACGATTGCC
GCCGCATTTGGCGGGACGACGACCATTATTGATTTTTGCTTAACGAATAAAGGTGAGCCC
CTGAAAAAAGCGATTGAAACTTGGCATAACAAAGCGACGGGGAAAGCGGTGATCGATTAC
GGGTTCCATTTGATGATCAGTGAAATAACGGACGATGTGCTTGAAGAGCTTCCAAAAGTG
ATCGAAGAAGAAGGAATTACCTCCTTTAAAGTATTTATGGCGTATAAAGATGTGTTTCAA
GCTGATGATGGAACCTTGTATCGGACGCTAGTCGCGGCAAAAGAACTCGGAGCGCTTGTC
ATGGTGCATGCCGAGAATGGAGACGTGATTGACTATTTAACGAAAAAAGCCTTGGAGGAC
GGGCATACTGATCCGATTTATCATGCATTAACGAGACCTCCAGAGCTAGAAGGAGAAGCG
ACGGGGCGCGCCTGTCAATTGACAGAACTCGCTGGTTCGCAATTGTACGTCGTTCATGTA
TCGTGTGCTCAAGCGGTAGAGAAAATTGCTGAAGCGCGCAATAAGGGGTTGAATGTATGG
GGCGAAACTTGTCCCCAGTATCTGGTGCTCGATCAGTCCTATTTAGAAAAGCCGAATTTT
GAAGGTGCTAAATATGTATGGTCACCGCCGCTTCGTGAGAAATGGCATCAAGAAGTGCTA
TGGAATGCCTTGAAAAACGGCCAGCTGCAAACGCTCGGATCTGACCAATGCTCATTTGAT
TTTAAAGGCCAAAAAGAATTAGGAAGGGGAGATTTTACCAAAATCCCAAATGGTGGTCCT
ATTATTGAGGATCGGGTGAGTATTCTTTTCAGTGAAGGAGTGAAAAAAGGGAGAATTACC
CTCAACCAGTTTGTTGATATTGTATCAACAAGAATCGCCAAATTGTTTGGTCTATTCCCG
AAGAAAGGAACCATTGCCGTCGGTGCGGATGCGGATTTAGTCATTTTTGATCCAACGGTT
GAACGGGTGATTTCAGCCGAAACACACCATATGGCTGTGGATTATAATCCGTTTGAAGGG
ATGAAAGTAACAGGGGAACCTGTGTCGGTTTTATGTAGAGGAGAATTTGTGGTACGTGAT
AAACAATTTGTCGGGAAACCGGGGTACGGCCAATATGTTAAACGCGCGAAATATGGGGCG
CTAATGGCCGACCAAGATGTGGTGAAAATGTCCTAA

# Drug_Target_4_General_Function:
Nucleotide transport and metabolism

# Drug_Target_4_General_References:
7765480	Mukohara Y, Ishikawa T, Watabe K, Nakamura H: A thermostable hydantoinase of Bacillus stearothermophilus NS1122A: cloning, sequencing, and high expression of the enzyme gene, and some properties of the expressed enzyme. Biosci Biotechnol Biochem. 1994 Sep;58(9):1621-6.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3122

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
51726

# Drug_Target_4_Name:
D-hydantoinase

# Drug_Target_4_Number_of_Residues:
471

# Drug_Target_4_PDB_ID:
1K1D

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_4_Protein_Sequence:
>D-hydantoinase
MTKLIKNGTIVTATDIYEADLLIQDGKIAVIGRNLDESGAEVIDATGCYVFPGGIDPHTH
LDMPFGGTVTKDDFESGTIAAAFGGTTTIIDFCLTNKGEPLKKAIETWHNKATGKAVIDY
GFHLMISEITDDVLEELPKVIEEEGITSFKVFMAYKDVFQADDGTLYRTLVAAKELGALV
MVHAENGDVIDYLTKKALEDGHTDPIYHALTRPPELEGEATGRACQLTELAGSQLYVVHV
SCAQAVEKIAEARNKGLNVWGETCPQYLVLDQSYLEKPNFEGAKYVWSPPLREKWHQEVL
WNALKNGQLQTLGSDQCSFDFKGQKELGRGDFTKIPNGGPIIEDRVSILFSEGVKKGRIT
LNQFVDIVSTRIAKLFGLFPKKGTIAVGADADLVIFDPTVERVISAETHHMAVDYNPFEG
MKVTGEPVSVLCRGEFVVRDKQFVGKPGYGQYVKRAKYGALMADQDVVKMS

# Drug_Target_4_Reaction:
5,6-dihydrouracil + H2O = 3-ureidopropanoate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
5,6-dihydrouracil + H(2)O = 3- ureidopropanoate

# Drug_Target_4_SwissProt_ID:
Q45515

# Drug_Target_4_SwissProt_Name:
HYDA_GEOSE

# Drug_Target_4_Synonyms:
DHPase
Dihydropyrimidinase
EC 3.5.2.2

# Drug_Target_4_Theoretical_pI:
4.93

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AJ606310

# Drug_Target_5_GenBank_ID_Protein:
38304072

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
Not Available

# Drug_Target_5_Gene_Sequence:
>1560 bp
ATGAGTCCGCGAGAAATTGAGGTTTCCGAGCCGCGCGAGGTTGGTATCACCGAGCTCGTG
CTGCGCGATGCCCATCAGAGCCTGATGGCCACACGAATGGCAATGGAAGACATGGTCGGC
GCCTGTGCAGACATTGATGCTGCCGGGTACTGGTCAGTGGAGTGTTGGGGTGGTGCCACG
TATGACTCGTGTATCCGCTTCCTCAACGAGGATCCTTGGGAGCGTCTGCGCACGTTCCGC
AAGCTGATGCCCAACAGCCGTCTCCAGATGCTGCTGCGTGGCCAGAACCTGCTGGGTTAC
CGCCACTACAACGACGAGGTCGTCGATCGTTTCGTCGACAAGTCCGCTGAGAACGGCATG
GACGTGTTCCGTGTCTTCGACGCCATGAATGATCCCCGCAATATGGCGCACGCCATGGCT
GCCGTCAAGAAGGCCGGCAAGCACGCGCAGGGCACCATTTGCTACACGATCAGCCCGGTC
CACACCGTTGAGGGCTATGTCAAGCTTGCTGGTCAGCTGCTCGACATGGGTGCTGATTCC
ATCGCCCTGAAGGACATGGCCGCCCTGCTCAAGCCGCAGCCGGCCTACGACATCATCAAG
GCCATCAAGGACATACGGCCAGAAGACGCAGATCAACCTGCACTGCACTCCACCACGGGT
GTCACCGAGGTCTCCCTCATGAAGGCCATCGAGGCCGGCGTCGACACCGCCATCTCGTCC
ATGTCGCTCGGCCCGGGCCACAACCCCACCGAGTCGGTTGCCGAGATGCTCGAGGGCACC
GGGTACACCACCAACCTTGACTACGATCGCCTGCACAAGATCCGCGATCACTTCAAGGCC
ATCCGCCCGAAGTACAAGAAGTTCGAGTCGAAGACGCTTGTCGACACCTCGATCTTCAAG
TCGCAGATCCCCGGCGGCATGCTGTCCAACATGGAGTCGCAGCTGCGCGCCCAGGGCGCC
GAGGACAAGATGGACGAGGTCATGGCAGAGGTGCCGCGCGTCCGAAGGCCGGCGCCGGTT
TTCCCCGCCCCTGGTCACCCCGTCCAGCCAGATCGTCGGCACGCAGGCCTGTTCAACGTG
ATGATGGGCGAGTACAAGAGGATGACCGGCGAGTTCGCAGATATCATGCTCGGCTACTAC
GGCGCCACGCCGGCCGATCGCGATCCGAAGTGGTCAGTTGGCGAGGAGCATCGCAGAGCG
ATCACCCAGCGCCCGGCCGATCACGATCCGAAGGTGGTCAAGTTGGCCGAGGAGCAGTCC
GGCAAGAAGCCGATCACCCAGCGCCCGGCCGATCTGCTGCCCCCCGAGTGGGAGGAGCAG
TCCAAGGAGCCGCGCCCTAAGGGCTTCAACGGCACCGACGAGGACGTGCTCACCTATGCA
CTGTTCCCGCAGGTCGCTCCGGTCTTCTTCGAGAGTCGGCCGAGGGCCGCAGAGGTGGCT
CTCACCGATGCCCAGCTGAAGGCCGAGGCGAGGGCGACGAGAAGTGTCGCCGTGGCCGGT
CCCGTCACCTACAACGTGAACGTGCGGAACCGTCCGCAAGTCACCGTTCAGCAGGCGTGA

# Drug_Target_5_General_Function:
Energy production and conversion

# Drug_Target_5_General_References:
8365490	Thornton CG, Kumar GK, Shenoy BC, Haase FC, Phillips NF, Park VM, Magner WJ, Hejlik DP, Wood HG, Samols D: Primary structure of the 5 S subunit of transcarboxylase as deduced from the genomic DNA sequence. FEBS Lett. 1993 Sep 13;330(2):191-6.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
2983

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
55650

# Drug_Target_5_Name:
Methylmalonyl-CoA carboxyltransferase 5S subunit

# Drug_Target_5_Number_of_Residues:
505

# Drug_Target_5_PDB_ID:
1RQE

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00682	HMGL-like
PF02436	PYC_OADA

# Drug_Target_5_Protein_Sequence:
>Methylmalonyl-CoA carboxyltransferase 5S subunit
MSPREIEVSEPREVGITELVLRDAHQSLMATRMAMEDMVGACADIDAAGYWSVECWGGAT
YDSCIRFLNEDPWERLRTFRKLMPNSRLQMLLRGQNLLGYRHYNDEVVDRFVDKSAENGM
DVFRVFDAMNDPRNMAHAMAAVKKAGKHAQGTICYTISPVHTVEGYVKLAGQLLDMGADS
IALKDMAALLKPQPAYDIIKAIKDTYGQKTQINLHCHSTTGVTEVSLMKAIEAGVDVVDT
AISSMSLGPGHNPTESVAEMLEGTGYTTNLDYDRLHKIRDHFKAIRPKYKKFESKTLVDT
SIFKSQIPGGMLSNMESQLRAQGAEDKMDEVMAEVPRVRKAAGFPPLVTPSSQIVGTQAV
FNVMMGEYKRMTGEFADIMLGYYGASPADRDPKVVKLAEEQSGKKPITQRPADLLPPEWE
KQSKEAATLKGFNGTDEDVLTYALFPQVAPVFFEHRAEGPHSVALTDAQLKAEAEGDEKS
LAVAGPVTYNVNVGGTVREVTVQQA

# Drug_Target_5_Reaction:
(S)-methylmalonyl-CoA + pyruvate = propanoyl-CoA + oxaloacetate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
The 5S subunit specifically catalyzes the transfer of the carboxyl group from biotin of the 1.3S subunit to pyruvate to form oxaloacetate and 1.3S biotin

# Drug_Target_5_SwissProt_ID:
Q70AC7

# Drug_Target_5_SwissProt_Name:
5S_PROFR

# Drug_Target_5_Synonyms:
EC 2.1.3.1
Transcarboxylase 5S subunit

# Drug_Target_5_Theoretical_pI:
5.51

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
U15029

# Drug_Target_6_GenBank_ID_Protein:
640031

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
iadA

# Drug_Target_6_Gene_Sequence:
>1173 bp
ATGATTGATTATACCGCAGCCGGTTTTACCCTGCTGCAGGGAGCGCATTTGTATGCGCCG
GAAGATCGGGGAATTTGCGATGTCCTCGTCGCTAACGGCAAAATTATCGCCGTTGCCAGC
AATATCCCTTCTGACATTGTACCGAACTGCACGGTTGTCGATCTCAGTGGGCAGATCCTC
TGCCCAGGTTTTATTGATCAACACGTCCATTTGATTGGCGGTGGCGGCGAAGCAGGTCCC
ACGACGCGCACGCCGGAAGTGGCGCTAAGTCGCCTGACGGAAGCGGGCGTCACGTCAGTG
GTTGGTCTGCTGGGCACCGACTCTATCTCTCGCCACCCGGAATCCCTGCTCGCCAAGACC
CGTGCGCTCAATGAAGAAGGCATCAGCGCCTGGATGCTGACCGGCGCTTATCATGTCCCT
TCCCGCACCATTACGGGTTCCGTGGAAAAAGACGTGGCGATTATCGATCGTGTGATTGGC
GTGAAATGCGCCATCTCTGATCACCGTTCTGCCGCACCGGACGTTTATCACCTGGCCAAT
ATGGCGGCAGAATCCCGCGTTGGCGGTTTGCTCGGCGGTAAACCTGGCGTCACCGTGTTC
CACATGGGCGACAGTAAAAAGGCGTTACAGCCTATTTATGACCTGCTGGAAAACTGCGAT
GTGCCGATCAGCAAGCTGCTGCCGACCCACGTTAACCGCAACGTACCGTTGTTTGAGCAG
GCGCTGGAGTTCGCGCGCAAAGGCGGCACCATCGATATCACCAGCAGCATTGACGAACCG
GTCGCCCCTGCCGAAGGTATTGCCCGCGCCGTTCAGGCGGGTATTCCGCTGGCACGCGTC
ACCCTCAGCTCCGACGGCAACGGTAGCCAGCCGTTCTTCGATGACGAAGGGAATTTAACC
CATATCGGTGTTGCCGGTTTTGAAACGTTGCTGGAAACCGTGCAGGTGCTGGTCAAAGAC
TATGATTTCAGTATCAGCGATGCCCTGCGCCCGCTCACCAGTAGCGTAGCCGGTTTCCTT
AACCTGACCGGGAAAGGCGAAATTCTGCCAGGCAATGATGCTGACTTGCTGGTCATGACG
CCAGAACTGCGCATTGAGCAGGTATACGCTCGCGGCAAACTGATGGTCAAAGACGGCAAA
GCCTGCGTGAAAGGAACGTTTGAAACGGCTTAA

# Drug_Target_6_General_Function:
Nucleotide transport and metabolism

# Drug_Target_6_General_References:
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
7876157	Gary JD, Clarke S: Purification and characterization of an isoaspartyl dipeptidase from Escherichia coli. J Biol Chem. 1995 Feb 24;270(8):4076-87.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3281

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
41084

# Drug_Target_6_Name:
Isoaspartyl dipeptidase

# Drug_Target_6_Number_of_Residues:
390

# Drug_Target_6_PDB_ID:
1YBQ

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01979	Amidohydro_1

# Drug_Target_6_Protein_Sequence:
>Isoaspartyl dipeptidase
MIDYTAAGFTLLQGAHLYAPEDRGICDVLVANGKIIAVASNIPSDIVPNCTVVDLSGQIL
CPGFIDQHVHLIGGGGEAGPTTRTPEVALSRLTEAGVTSVVGLLGTDSISRHPESLLAKT
RALNEEGISAWMLTGAYHVPSRTITGSVEKDVAIIDRVIGVKCAISDHRSAAPDVYHLAN
MAAESRVGGLLGGKPGVTVFHMGDSKKALQPIYDLLENCDVPISKLLPTHVNRNVPLFEQ
ALEFARKGGTIDITSSIDEPVAPAEGIARAVQAGIPLARVTLSSDGNGSQPFFDDEGNLT
HIGVAGFETLLETVQVLVKDYDFSISDALRPLTSSVAGFLNLTGKGEILPGNDADLLVMT
PELRIEQVYARGKLMVKDGKACVKGTFETA

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Catalyzes the hydrolytic cleavage of a subset of L- isoaspartyl (L-beta-aspartyl) dipeptides. Used to degrade proteins damaged by L-isoaspartyl residues formation. The best substrate for the enzyme reported thus far is iso-Asp-Leu

# Drug_Target_6_SwissProt_ID:
P39377

# Drug_Target_6_SwissProt_Name:
IADA_ECOLI

# Drug_Target_6_Synonyms:
EC 3.4.19.-

# Drug_Target_6_Theoretical_pI:
4.89

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
M25261

# Drug_Target_7_GenBank_ID_Protein:
154222

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
bla

# Drug_Target_7_Gene_Sequence:
>828 bp
ATGGCAATCCGAATCTTCGCGATACTTTTCTCCATTTTTTCTCTTGCCACTTTCGCGCAT
GCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCC
AAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGAT
CCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTT
TTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTT
AACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCT
ACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTAT
TTGAAGAAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATA
GAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGT
AACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAA
GCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGG
GTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCA
AACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATT
GAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAA

# Drug_Target_7_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_7_General_References:
2538329	Mossakowska D, Ali NA, Dale JW: Oxacillin-hydrolysing beta-lactamases. A comparative analysis at nucleotide and amino acid sequence levels. Eur J Biochem. 1989 Mar 15;180(2):309-18.
2689593	Nucken EJ, Henschke RB, Schmidt FR: Nucleotide sequence of an OXA-2 beta-lactamase gene from the R-plasmid R1767 derived plasmid pBP11 and comparison to closely related resistance determinants found in R46 and Tn2603. J Gen Microbiol. 1989 Apr;135(4):761-5.
3876949	Dale JW, Godwin D, Mossakowska D, Stephenson P, Wall S: Sequence of the OXA2 beta-lactamase: comparison with other penicillin-reactive enzymes. FEBS Lett. 1985 Oct 21;191(1):39-44.
6335398	Holland S, Dale JW: Improved purification and characterization of the OXA-2 beta-lactamase. Biochem J. 1984 Dec 15;224(3):1009-13.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3237

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
31686

# Drug_Target_7_Name:
Beta-lactamase OXA-2

# Drug_Target_7_Number_of_Residues:
275

# Drug_Target_7_PDB_ID:
1K38

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00905	Transpeptidase

# Drug_Target_7_Protein_Sequence:
>Beta-lactamase OXA-2 precursor
MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFD
PVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNS
TVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSLAISAQEQIAFLRKLYR
NELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTP
NRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR

# Drug_Target_7_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_7_Signals:
1-21

# Drug_Target_7_Specific_Function:
This is an oxacillin-hydrolyzing beta-lactamase

# Drug_Target_7_SwissProt_ID:
P0A1V8

# Drug_Target_7_SwissProt_Name:
BLO2_SALTY

# Drug_Target_7_Synonyms:
Beta-lactamase OXA-2 precursor
EC 3.5.2.6
Penicillinase

# Drug_Target_7_Theoretical_pI:
9.77

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
AF165881

# Drug_Target_8_GenBank_ID_Protein:
5690425

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
dadX

# Drug_Target_8_Gene_Sequence:
>1074 bp
ATGCGCCCCGCCCGTGCCCTGATCGACCTGCAAGCCCTTCGTCACAACTATCGGCTGGCC
CGCGAGGCCACCGGCGCCCGTGCGCTCGCGGTGATCAAGGCGGACGCATACGGCCACGGC
GCGGTGCGCTGTGCCGAAGCGCTGGCGGCCGAGGCCGATGGCTTCGCCGTGGCCTGCATC
GAGGAAGGCCTGGAGCTGCGCGAGGCCGGTATCCGCCAGCCGATCCTGCTGCTGGAGGGC
TTCTTCGAGGCGTCCGAGCTGGAGCTGATCGTCGCCCACGACTTCTGGTGCGTGGTGCAT
TGCGCCTGGCAATTGGAGGCGATCGAACGCGCCAGCCTGGCCCGCCCGCTGAACGTCTGG
CTGAAGATGGATTCGGGCATGCACCGCGTCGGCTTCTTCCCCGAGGACTTCCGCGCCGCC
CACGAGCGCCTGCGGGCCAGCGGCAAGGTGGCCAAGATCGTGATGATGAGCCACTTCTCC
CGCGCCGACGAACTGGATTGCCCGCGCACCGAGGAACAGCTCGCCGCCTTCTCGGCCGCG
AGCCAGGGCCTGGAAGGCGAGATCAGCCTGCGCAATTCGCCAGCCGTGCTCGGCTGGCCG
AAGGTGCCCAGCGATTGGGTACGTCCGGGCATCCTGCTCTACGGAGCCACGCCGTTCGAG
CGCGCACATCCGCTGGCCGACCGCTTGCGCCCGGTGATGACCCTGGAATCGAAGGTGATC
AGCGTCCGCGACCTGCCGGCCGGCGAACCGGTCGGCTACGGCGCGCGCTACAGCACGGAG
CGTAGGCAGCGCATCGGCGTGGTCGCCATGGGCTACGCGGATGGCTACCCGCGCCACGCC
GCCGACGGCACCCTTGTGTTCATCGACGGCAAGCCGGGGCGCCTGGTTGGCCGGGTATCG
ATGGACATGCTCACCGTCGACCTTACCGACCATCCCCAGGCCGGGCTGGGCAGCCGGGTC
GAACTATGGGGTCCGAACGTGCCGGTCGGCGCCCTGGCGGCGCAGTTCGGCAGCATTCCC
TACCAGCTGTTGTGCAACCTGAAAAGGGTGCCGCGCGTCTATTCCGGGGCTTGA

# Drug_Target_8_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_8_General_References:
10977898	Strych U, Huang HC, Krause KL, Benedik MJ: Characterization of the alanine racemases from Pseudomonas aeruginosa PAO1. Curr Microbiol. 2000 Oct;41(4):290-4.
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
3292

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
38915

# Drug_Target_8_Name:
Alanine racemase, catabolic

# Drug_Target_8_Number_of_Residues:
357

# Drug_Target_8_PDB_ID:
1RCQ

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00842	Ala_racemase_C
PF01168	Ala_racemase_N

# Drug_Target_8_Protein_Sequence:
>Alanine racemase, catabolic
MRPARALIDLQALRHNYRLAREATGARALAVIKADAYGHGAVRCAEALAAEADGFAVACI
EEGLELREAGIRQPILLLEGFFEASELELIVAHDFWCVVHCAWQLEAIERASLARPLNVW
LKMDSGMHRVGFFPEDFSAAHERLRASGKVAKIVMMSHFSRADELDCPRTEEQLAAFAAA
SQGLEGEISLRNSPAVLGWPKVPSDWVRPGILLYGATPFERAHPLADRLRPVMTLESKVI
SVRDLPAGEPVGYGARYSTERSQRIGVVAMGYADGYPRHAADGTLVFIDGKPGRLVGRVS
MDMLTVDLTDHPQAGLGSRVELWGPNVPVGALAAQFGSIPYQLLCNLKRVPRVYSGA

# Drug_Target_8_Reaction:
L-alanine = D-alanine

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Isomerizes L-alanine to D-alanine which is then oxidized to pyruvate by dadA

# Drug_Target_8_SwissProt_ID:
Q9HTQ2

# Drug_Target_8_SwissProt_Name:
ALR2_PSEAE

# Drug_Target_8_Synonyms:
EC 5.1.1.1

# Drug_Target_8_Theoretical_pI:
6.85

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
Not Available

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
AE000511

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
HP_0602

# Drug_Target_9_Gene_Sequence:
>657 bp
GTGTTGGATAGTTTTGAGATTTTAAAGGCTTTAAAGAGCTTGGATTTATTGAAAAACGCC
CCTAGTTGGTGGTGGCCTAACGCTTTGAAATTTGAAGCTTTATTAGGGGCGGTTTTAACG
CAAAATACTAAATTTGAAGCCGTTTTGAAATCTTTAGAAAATTTAAAAAACGCTTTCATT
TTAGAAAATGATGATGAGATCAATCTTAAAAAAATCGCTTATATAGAGTTTTCAAAGCTT
GCAGAGTGTGTCCGCCCTAGCGGGTTTTATAACCAAAAAGCCAAACGACTGATTGATTTG
AGTAAGAATATTTTAAAAGACTTTCAAAGTTTTGAAAATTTTAAACAAGAAGTAACCAGA
GAGTGGCTTTTAAACCAAAAGGGCGTTGGCAAAGAAAGCGCGGATGCGATTTTATGCTAT
GTGTGCGCTAAAGAAGTGATGGTGGTGGATAAATATAGCTATCTTTTTTTAAAAAAAATA
GGCATAGAGATAGAAGATTATGACGAATTGCAACATTTTTTTGAAAAAGGCGTTCAAGAG
AATTTAAATTCCGCCTTAGCGCTTTATGAAAACACCATTCCTTTAGCGCAACTTTATGCG
AGATTCCATGGAAAGATCGTAGAATTTTCCAAACAAAAATTGGAATTAAAACTTTGA

# Drug_Target_9_General_Function:
Involved in catalytic activity

# Drug_Target_9_General_References:
14517230	Eichman BF, O'Rourke EJ, Radicella JP, Ellenberger T: Crystal structures of 3-methyladenine DNA glycosylase MagIII and the recognition of alkylated bases. EMBO J. 2003 Oct 1;22(19):4898-909.
9252185	Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
4549

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
25287

# Drug_Target_9_Name:
Endonuclease III

# Drug_Target_9_Number_of_Residues:
218

# Drug_Target_9_PDB_ID:
1PU7

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00633	HHH
PF00730	HhH-GPD

# Drug_Target_9_Protein_Sequence:
>Endonuclease III
MLDSFEILKALKSLDLLKNAPSWWWPNALKFEALLGAVLTQNTKFEAVLKSLENLKNAFI
LENDDEINLKKIAYIEFSKLAECVRPSGFYNQKAKRLIDLSKNILKDFQSFENFKQEVTR
EWLLNQKGVGKESADAILCYVCAKEVMVVDKYSYLFLKKIGIEIEDYDELQHFFEKGVQE
NLNSALALYENTIPLAQLYARFHGKIVEFSKQKLELKL

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
O25323

# Drug_Target_9_SwissProt_Name:
O25323_HELPY

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
6.55

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03801
